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Abstract

Studies have shown that mesenchymal stromal cells (MSCs) are able to differentiate
into extra-mesodermal lineages, including neurons. Positive outcomes were obtained
after transplantation of neurally-induced MSCs in rats, rabbits and guinea pigs after
nerve injury, but the effect of these cells is unknown in horses. Our objective was to
test the ability of equine mesenchymal stromal cells to differentiate into cells of
neuronal lineage, and to assess differences, if any, in morphology and protein
expression. Additionally, we wanted to investigate if horse age and cell passage
number contributed to the ability to achieve neural differentiation.

The first part of this research focuses on assessing the potential of equine bone
marrow-derived mesenchymal stromal cells to undergo differentiation into cells of
neural lineage cells after prior demonstration of their stemness. It describes the
optimization of in vitro conditions to induce neural differentiation of equine MSCs and
the use of neural markers in equine MSCs, which has not been previously reported.

Subsequent research focuses on further commitment of these neural cells into
Schwann-like cells for possible transplantation into an acute peripheral nerve injury
model in horses. After optimizing the laboratory conditions to induce Schwann cell
differentiation of equine MSCs, their detachment from the tissue culture flasks
resulted in poor viability. Therefore, undifferentiated MSCs were transplanted in the
surrounding fascia after transecting the central portion of the anastomotic branch
(ramus communicans) of the lateral and medial palmar nerves of the fore limbs in
healthy horses. Approximately 45 days after the lesion was created, the whole nerve
was removed for histological analyses.
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INTRODUCTION

Horses (Equus caballus) are herbivore-domesticated mammals that have played a
crucial role in the development of the modern society. Several breeds of horses have
been used through the years for transportation, work in agriculture, wars, racing,
sources of food, equestrian sports, and pets. Furthermore, the horse industry has a
direct effect on the economy of the USA of $39 billion per year, and $102 billion when
the industry suppliers and employees factors are taken in consideration.1 The
profound impact of the horse industry on the economy results from the creation of
jobs, necessity of industrial supplies, agricultural production, generation of taxes, and
entertainment investments. Veterinary medicine is, therefore, one important science
to safeguard the stability of the horse industry.

There are several breeds of horses (equines), most of which possess certain corporal
characteristics that allow them to perform arduous physical work under various
environmental conditions. Some of these anatomic and functional characteristics
include a particular musculoskeletal system, a complex gastrointestinal system, and a
high efficiency cardiovascular and respiratory apparatuses, that will provide them
with satisfactory kinematics, energy, and adequate perfusion and oxygenation,
respectively. Because horses are athletic animals and approximately 44-53% of their
body weight is constituted solely by muscle,2 a disturbance of any of the structures of
the musculoskeletal system (i.e. muscles, tendons, bones, joints, ligaments, and their
associated blood and lymphatic vessels, and nerves) will produce poor performance
and, consequently, financial or emotional losses. The musculoskeletal system of the
horse is vast; in this research, however, a particular interest is given to the structures
that deliver sensory and motor input to the musculoskeletal system of the horse: the
peripheral nerves.

1

CHAPTER I:
LITERATURE REVIEW
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Abstract

Peripheral nerve injuries occur commonly in horses but the available options for
managing them are limited. Cell therapy via autograft is the preferred method for
nervous tissue repair in human medicine but there are high risks for complications at
the donor site and the number of Schwann cells yielded from this donor nerve is
generally low. Cell therapy via transplantation of autogeneic or allogeneic
mesenchymal stromal cells (MSCs) provides an alternative approach for yielding high
number of cells without the risks of causing damage to the donor site; it has also
revealed promising results after transplantation in peripheral nerve injuries
artificially created in laboratory animals or when transplanted in clinical cases in dogs
and humans, but this is unknown in horses. Based on in vitro studies, MSCs have antiinflammatory, immunomodulatory, and paraendocrine properties that provide the
conditions necessary for tissue repair. The method of delivery of these cells has largely
been studied and might depend on the site of lesion and practicability of the
procedure. Further research is necessary for evaluating methods of labeling, tracking
and delivering these cells in horses suffering from peripheral nerve injuries.

Generalities of the nervous system

The nervous system involves a complex network of cells that ultimately has the
functions of acquiring information from the exterior of the animal, processing it, and
delivering specific signals to specific organs based on these external stimuli. It is,
therefore, that the nervous system is composed of different specialized cells, which
originate from the ectodermic layer during the embryonic development.

The nervous system is divided into the central nervous system (CNS) and the
peripheral nervous system (PNS). Briefly, the CNS comprises the structures within
the encephalon (i.e. brain, brain stem, cerebellum, etc.) and spinal cord. On the other
hand, ganglia, cranial and spinal nerves comprise the PNS.3 It is worth mentioning
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that both divisions of the nervous system continuously interact with each other. For
purposes of this research, however, a particular interest is given to the PNS.

Additionally, the PNS is subdivided into autonomic PNS and somatic PNS. The
autonomic PNS encompasses the nerve fibers (axons) that innervate involuntary or
autonomic structures, such as the heart, smooth muscle and glands.3 The somatic PNS,
instead, involves the axons that give input to the musculoskeletal system, which are
mostly involved with voluntary activity.

An alternative division of the nervous system is based in its functional properties:
afferent (sensory) and efferent (motor).4

Peripheral nerves. These include the 12 pairs of cranial nerves located in the encephalon,
and the spinal nerves, which arise from the spinal cord. Each nerve consists of parallel
bundles of nerve fibers (axons), which can be afferent or efferent. A surrounding
sheath of connective tissue provides support to these nerves and their associated
blood and lymphatic vessels. Additionally, these axons can be myelinated or nonmyelinated.4 Myelinated axons are surrounded by a myelin sheath formed by
supporting cells (also known as satellite cells): oligodendrocytes, in the CNS; and
Schwann cells in the PNS. Myelin is composed of the cell membrane from Schwann
cells, which is approximately 80% lipid in nature; hence, it has insulation properties.
The myelin sheath surrounding the axon is a layer regularly segmented by the nodes
of Ranvier that help in the transmission of a nerve impulse in a saltatory and extremely
fast manner (Figure 1.1). Peripheral nerves, consequently, can also be classified by
their speed of conduction (A, B or C fibers) and their fiber size (μm of diameter).5 The
fastest nerve fibers are usually myelinated and thicker (i.e. α and β subtypes of the A
fibers, which transmit motor and sensory impulses to skeletal muscle and skin
receptors). On the other hand, the slowest nerve fibers are non-myelinated and of
small diameter (i.e. C fibers that transmit deep, non-localized pain).
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In the CNS, each oligodendrocyte forms myelin sheaths for up to 60 axons. In the PNS,
on the other hand, only one Schwann cell exists for each segment of one axon.
Moreover, the Schwann cells wrap around the axons in a spiral, which is clockwise in
some segments and counterclockwise in others. These wrappings become tight as the
axon matures, and the thickness of the myelin sheath will ultimately depend on the
number of spirals of a Schwann cell membrane.

Figure 1.1 Peripheral nerve myelination

Peripheral nerve conduction. Once a stimulus is perceived, an action potential (nerve
impulse) starts at the initial segment of an axon and propagates along the plasma
membrane of the cell. Before an action potential the interior of a nerve cell is negatively
charged at approximately -80 millivolts (mV); this is called the resting membrane
potential. The cell membrane allows the opening of ion channels that result in a rapid
influx of ions, which will change the charge inside the cell. This change is called
depolarization.3 Ion channels are particular to the cell type. For example, sodium
channels are abundant in peripheral nerves; they open fast and allow a massive
entrance of sodium inside the cell that will result in an extremely prompt action
potential. Calcium channels are abundant on smooth muscle cells; they open in a
slower manner, resulting in a more prolonged action potential. Finally, after the
impulse has propagated throughout the cell, other ion channels (e.g. potassium) open
and allow the exit of positive ions, so the original resting membrane potential can be
restored (hyperpolarization).
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The speed of conduction is correlated with the axonal diameter of the nerve fiber.
Additionally, myelin sheath thickness correlates with nerve diameter. These
characteristics and the saltatory conduction of the nerve impulse at the nodes of
Ranvier in myelinated nerves make myelinated nerves the fastest nerves for
transmission of an impulse, at a velocity of 70-120 meters per second in Aα fibers.

Concepts in regenerative medicine: stem cells

The purpose of regenerative medicine is to create functional tissues for repairing or
replacing tissues or organs that have been damaged or lost because of accidents,
diseases, and age,6 usually via transplantation of cells, tissues or organs that were
previously cultured or created in the laboratory.

Stem cells are undifferentiated cells that have the ability to proliferate (self-renew) for
an indeterminate time during the life of the organism, and to differentiate into mature,
specialized cells given the right conditions (plasticity).6,7 The term “stem cell”,
however, has been used indiscriminately to denote certain types of cells with specific
characteristics and it is, therefore, important to clarify some terms used in the field of
cellular therapy for regenerative medicine.

Stem cells can be of embryonic or adult origin. Based on their ability to differentiate,
those stem cells capable of differentiating into all cell types, including extra-embryonic
membranes and tissues, are called totipotent stem cells and they are solely found in the
zygote and early embryo.6,8 Pluripotent stem cells are able to differentiate into all cell
types from the 3 germinal layers that constitute an implanted embryo (ectoderm,
mesoderm and endoderm), but not into extra-embryonic tissues.6,7 Multipotent stem
cells are capable of differentiating into various cell types of a specific germinal layer.
Finally, unipotent stem cells can only differentiate into a single mature cell type.6
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Types of cell transplants. Depending on the source, cell, tissue, or organ, transplants are
called xenogeneic, allogeneic or autologous. Briefly, xenogeneic implies the
transplantation of cells, tissue or organs from one species to another; for example,
human cell transplants into rats for research purposes. Allogeneic transplantation
involves different individuals from the same species; for example, human blood
donors. Autologous transplantation involves taking tissue from an individual in order
to implant it at another site on that same individual (also known as autograft); for
example, removal of a portion of the ischium bone in order to graft it into a bone defect
(in a bone other than ischium).

In human and veterinary practice, the source of transplants is either allogeneic or
autologous. The concern in performing allogeneic transplantation of cells, tissue or
organs is the possibility of rejection, which is due to the immune response of the host.
A disadvantage of autologous transplantation is the possibility of causing morbidity
at the donor site, which was previously inexistent.

Mesenchymal stromal cells (MSCs)

This term refers to non-hematopoietic (non-blood) adult multipotent stem cells that
originate from diverse adult tissues. It is unknown if these cells are the same
throughout the different tissues.8 The term mesenchyme denotes a transient, loose
tissue conformed by cells within a mesh of fluid and extracellular protein matrix,
during embryonic and fetal development. It is mainly derived from the mesoderm
and it directly gives rise to connective tissue throughout the body and to most organs
in the body (morphogenesis) after interacting with the epithelium.9 The mesenchyme,
consequently, is crucial in the embryonic life, but can also be found in small quantities
in bone marrow, fat, muscles, and dental pulp. The term stromal, on the other hand,
refers to cells that constitute the connective tissue of every organ. 6 Certain
mesenchymal stromal cells (MSCs) are capable of displaying multipotency and are
subsequently called mesenchymal stem cells.10,11
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Criteria for MSCs

To properly refer to MSCs, the International Society for Cellular Therapy (ISCT) has
specified that “multipotent mesenchymal stromal cells” is a term preferred over
mesenchymal stem cells, because not all have stem cell characteristics. Three minimal
criteria for defining human MSCs have been established: 1. adherence to plastic when
maintained in standard culture conditions, 2. expression of specific surface antigens,
and 3. potential for multipotent mesenchymal differentiation (plasticity).10

It is important to mention that currently there is controversy on the use of the
terminology regarding mesenchymal stem cells and mesenchymal stromal cells
(MSCs).12 There is lack of a specific marker expressed solely by MSCs. Several
characteristics of these cells, however, have been taken in conjunction to propose the
minimal criteria to define MSCs.10 In addition, there are differences between MSC
populations obtained from various sources, adding confusion to the concept of MSC.

Surface antigen expression of MSCs. The recognition of surface antigens permits the
identification of a particular cell population. When performing flow cytometry,
approximately 95% of the MSC population should mainly express CD73, CD90 and
CD105 surface antigens. The MSCs should also lack expression of the hematopoietic
antigens CD45, CD34, CD14, CD11b, CD19 and human leukocyte antigen (HLA) class
II.10 It is important to mention that for a proper identification of a MSC population. It
is, consequently, important that the three criteria established by the ISCT are taken
simultaneously in consideration for defining MSC.
Sources of MSCs

Mesenchymal stromal cells have been isolated from various tissues in humans, pigs,
rodents, rabbits, dogs, cats, small ruminants,13 and horses.14 The most commonly
identified sources for MSC isolation are adult adipose tissue15 bone marrow, compact
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bone, dental pulp,16 peripheral blood,17 umbilical cord blood, amniotic fluid, and other
fetal tissues.18,19

Bone marrow-derived versus adipose tissue-derived MSCs. Because of the relative ease of
accessibility, MSCs are most commonly obtained from bone marrow and adipose
tissue in human and veterinary medicine. Bone marrow aspiration is considered an
invasive procedure in human medicine, but in equine medicine this is not the case
because of the relative straightforwardness of the procedure when aspirating bone
marrow from the sternum or the hip in horses. Bone marrow aspiration is also faster
and leads to less complications than aspirating adipose tissue for obtaining MSCs
from a horse.

Both bone marrow-derived and adipose tissue-derived MSCs are effective in their
ability to differentiate into cells of mesodermal and extra-mesodermal lineages and
both are able to express the aforementioned typical markers for MSCs. Furthermore,
cells derived from both sources appear to be similarly proliferative, although it has
been reported by some groups that adipose tissue-derived MSCs may yield higher
numbers of MSCs.20 And, most importantly, both sources of MSCs seem to have
immunosuppressive and anti-inflammatory properties.

Biological features of MSCs

By definition MSCs are multipotent and self-renew quickly. These features make
MSCs an alternative source for tissue regeneration. Additionally, regardless of their
source, it has been reported that these cells are well tolerated by the host after
transplantation (allogeneic transplantation).

Immunomodulatory properties of MSCs. After transplantation, MSCs are well tolerated
by the host. In vitro research has proved that MSCs are immunosuppressive by their
ability to inhibit activated cytotoxic T cells and natural killer cell proliferation, and
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downregulate B cell proliferation and differentiation.21,22 Furthermore, this feature
appears to be augmented if an active inflammatory response occurs in the body.
Likewise in animal models, MSCs were able to ameliorate or inhibit acute rejection
and or prolong allograft survival.22,23 An explanation for this would be the ability of
MSCs to downregulate CD86 and MHC class II to consequently impair the ability of
macrophages to activate the antigen-specific CD4+ T cells.24

More recently, it has been discovered that human bone marrow-derived MSCs express
toll-like receptors (TLR) 3 and 4.25 These TLR are involved in danger signals that
certain cells produce after they have been invaded by microorganisms, endotoxins or
certain nucleic acids, activating the inflammatory cascade and preventing the
suppression of T cell proliferation. Therefore, MSCs have the potential for both
inhibitory and stimulatory effects on the immune system.

Anti-inflammatory properties of MSCs. During acute inflammation, the body produces
both pro-inflammatory and anti-inflammatory cytokines (mainly, interleukins β1 [ILβ1] and 6 [IL-6], and tumor necrosis factor α [TNFα]) and other factors in an attempt
to defend itself from the insult, but also to enhance healing. Over-production of proinflammatory factors produces undesirable effects in the body, because it results in an
exaggerated inflammatory response. There are reports of MSCs being able to
counteract the effects of inflammation. Mesenchymal stromal cells are capable of
upregulating TGF-β1, an anti-inflammatory cytokine, shifting the macrophage
phenotype from M1 (inflammatory) to M2 (anti-inflammatory), secreting superoxide
dismutase, an enzyme that helps reduce oxidative stress, stimulating the synthesis of
other chemokines or growth factors, and recruiting other cells to the site of injury.26-29
On the other hand, MSCs are able to over produce prostaglandin E2 at levels that
would suppress the synthesis of the pro-inflammatory cytokines IL-6, TNFα and NFκB.24,25
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Additionally, MSCs are capable of migrating and homing into injured tissues and
even though the mechanisms have not been discovered yet, it is thought that tyrosine
kinase and TLR-3 receptors might mediate their activity.25,30

Paracrine influence of MSCs in tissue regeneration. It is alleged that MSCs enhance tissue
regeneration not only by their ability to stimulate endogenous progenitor or stem cells
or to differentiate into cells of other lineages, but also in an indirect manner by
secreting growth factors which are involved in neo-vascularization and tissue
protection (i.e. reducing oxidative stress), and by inhibiting the host’s immune
response after transplantation and promotion of healing.

Growth factors are extra-cellular macromolecules that influence the function of target
cells by binding to a cell surface receptor. Similarly, direct cell membrane-to-cell
membrane contact mediated by adhesion molecules might also influence the function
of other cells.31 For example, MSCs are known to secrete insulin-like growth factor 1
(ILGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (fGF2), platelet-derived growth factor (pdGF), nerve growth factor (NGF), hepatocyte
growth factor (hGF), and several interleukins (IL).15,26,32-34 The secretion of these
factors is triggered by different stimuli, such as hypoxia, ischemia, and free radicals.

The direct and indirect effects of MSCs are vast and still incompletely understood.
Research performed in laboratory animals for nervous system diseases such as
Alzheimer’s disease, spinal cord injuries, or peripheral nerve injuries has
demonstrated that the transplantation of MSCs provide neuroprotective effects by
reducing neuronal sensitivity to glutamate, reducing oxidative stress and apoptosis,
inhibiting the production of extracellular matrix, and by stimulating the synthesis of
growth factors needed for regeneration.26,35,36
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Cell plasticity of MSCs.

As recognized by the ISCT, MSCs should be capable of acquiring phenotypic markers
for osteoblasts, chondrocytes and adipocytes, under the proper culture conditions.37
To demonstrate this, staining with Alizarin Red for osteoblasts, Alcian Blue for
chondrocytes, and Oil-Red-O for adipocytes should be performed.10,38 Mesenchymal
stromal cells from bone marrow and adipose tissue, however, have also been
demonstrated to differentiate into cells from other mesodermal lineages (i.e.
myocytes, cardiac myoblasts, tenocytes, fibroblasts)39,40 and into cells of extramesodermal lineages (i.e. hepatocytes and neuronal cells).41-43

Neural differentiation of MSCs. In vitro research has shown that after induction with
specific culture medium MSCs suffer morphological changes, such as contraction of
the cell body and appearance of one or multiple processes, which resemble the
phenotype of a cell from neural.41,44-48 Several researchers refer to these cells as
“neuron-like cells” but this term has not been defined by the ISCT. Yet, these cells
continue to modify their morphology after the culture medium conditions are further
changed. For instance, after exposing MSCs to a cytokine cocktail composed mainly
of growth factors following previous pre-incubation with beta-mercaptoethanol and
all-trans-retinoic acid, these cells acquire a different phenotype than the typical
fibroblast-like morphology of an undifferentiated MSC; fibroblasts are flat and lack
structural assymetry.44,49-52 The morphological features that these MSCs acquire after
exposure to this media resemble those of a Schwann cell, that is an oval-shaped cell
body and bipolar or tripolar extensions, giving an overall spindle shape. Furthermore,
these cells are able to express specific protein markers of Schwann cell.34,44,50,53 And,
most remarkably, models in laboratory animals have demonstrated that the functional
properties of these cells after transplantation during spinal cord or peripheral nerve
injury promote myelination and axonal regeneration of the spinal cord or injured
nerve segments,45,48,52,54,55 demonstrating that MSCs have broader plasticity than
previously thought. Researchers refer to these cells as “Schwann-like cells”.
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The complete mechanisms that mediate the fate of these MSCs towards neural
commitment are currently unknown. It has been discovered, however, that there is a
transcriptional switch of MSCs towards neuroglial lineage, mediated by betamercaptoethanol and all-trans-retinoic acid.51 Furthermore, there are also pro-neural
genes that code for proteins that will eventually determine the fate of progenitor cells
and their differentiation.56,57

Caution needs to be taken, nevertheless, not to confuse the term “neuron-like cells”
with neurons. This term denotes MSCs (mesodermal origin) that were chemically
induced for differentiation and acquired certain morphological characteristics, which
is unrelated to the development of any of the nervous system cells, including neurons.
During embryological development, the neural crest cells migrate in different
directions and give rise to various ectodermal and mesodermal cell populations,
including neurons, supportive cells of the nervous system (glial cells, Schwann cells,
meningeal cells), endocrine cells (adrenal medulla, calcitonin-producing cells, carotid
body cells), and mesodermal derivatives (connective and skeletal tissue of the head,
smooth muscle cells on large vessels, and dermis of the neck and face). The fate of the
neural crest cells depends on where they migrate and stay, but it is thought that some
neural crest cells were already committed to their fate, while others are multipotent.58
The term “neuron-like cell”, consequently, should be avoided when referring to
MSCs. A more appropriate terminology should be proposed, but for purposes of this
research the term “neuron-like cells” will be replaced with “neural crest-like cells”.

Schwann cell trans-differentiation of MSCs. Transdifferentiation implies further
commitment or specialization of the cells’ fate in the cascade of neural differentiation,
in this case, towards a Schwann cell phenotype. Dezawa et al (2001) described a
protocol for the differentiation of MSCs into Schwann-like cells. This protocol
involved pre-incubation of the MSCs with beta-mercaptoethanol for 24 h, and alltrans-retinoic acid for 3 days; this was then replaced by a cytokine cocktail containing
basic fibroblastic growth factor (bFGF), pdGF, forskolin and heregulin (a type of
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neuregulin-1), for 7 days.52 Other researchers have done some modifications of this
protocol.

It has been hypothesized that MAPK signaling is involved in the differentiation of
Schwann precursor cells to mature Schwann cells (myelin producing Schwann cells).
The combination of some growth factors, such as bFGF and PDGF, stimulate the
activation of this MAPK cascade,59 while the role of forskolin is to upregulate the
levels of intracellular cAMP for proliferation.60 This upregulation of cAMP has
additional neuroprotective effects; it retards diffuse axonal damage and has antiinflammatory and immunomodulatory functions.61 Other factors, such as Krox-20,
activate the myelin genes and thus promote maturation of these Schwann cell
precursors;46,57 Krox-20 also suppresses the Notch signaling that is involved in
proliferation of glial cells, including the Schwann cell precursors.58,62 Similarly,
heregulin influences proliferation, survival and maturation of glial cells, by inducing
neural crest cells into Schwann cells via the MAPK cascade.57

Peripheral nerve injuries in the horse

Nerves can be injured because of trauma, toxicity, metabolic, or infectious disease.
Less frequently, degenerative and hereditary disorders pose a threat. Trauma to the
peripheral nerves can result from thermal or chemical injuries, compression, crushing,
stretching or transection.26,63 Following injury the blood-nerve barrier permeability
increases and a cascade of events leads to the activation of local macrophages and
monocytes that will remove myelin and axon debris, and to Schwann cell proliferation
that will produce neurotrophic factors and extracellular matrix molecules needed for
axonal regrowth and re-myelination. This inflammatory response results in Wallerian
degeneration in the distal stump of the injured nerve.26,30,35,46-48,56,58,63,64
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In veterinary practice, there are numerous peripheral nerve disorders (neuropathies)
commonly observed in horses depending on their physical activity, clinical status or
environment. Examples of these neuropathies include stringhalt, recurrent left
laryngeal neuropathy (laryngeal hemiplegia), suprascapular nerve injury (Sweeney),
facial, radial and femoral nerve paralysis, and polyneuritis equi (Figure 1.2). All of
these are a cause of poor performance and economic loss to the equestrian industry.
Furthermore, horses with peripheral nerve disorders are difficult to manage, and
clinicians rely primarily on treating affected horses with anti-inflammatory drugs and
physical therapy. Their treatment often results in financial hardship for the owner,
and the outcome is usually correlated with the severity of the lesion and the interval
before initiation of treatment. The final outcome for the horse is sometimes euthanasia.

Figure 1.2 Examples of peripheral nerve disorders in horses: laryngeal hemiplegia (a)
and stringhalt (b)

Types of nerve injuries

A classification for peripheral nerve injuries based on the severity of damage and
nervous components involved was described by Seddon (1943).65 The least severe
damage to the nerve is called neurapraxia, which is characterized by local ischemia
15

(lack of blood perfusion) and discriminatory demyelination of the myelin sheath; this
is reversible and the continuity of the axon itself is intact, thus conduction within the
nerve proximal and distal to the lesion remains intact. An example of this is the
damage that results from prolonged nerve compression.

The second type of injury is axonotmesis, in which there is disruption of the myelin
sheath and the axon. Here, the connective tissue layers surrounding bundles of axons
and their associated blood and lymphatic vessels, perineurium and epineurium,
remain intact. This injury results in Wallerian degeneration and part of the axon
disintegrates distal to the site of injury. Examples of this are nerve damage following
displaced fractures and nerve crush injuries.

Finally, the most severe type of nerve injury based on this classification is neurotmesis,
in which there is complete nerve transection and, therefore, disruption of the axons,
myelin and the endoneurium (the immediate connective tissue layer that engulfs
axons). This also results in Wallerian degeneration but there is complete transection
of the nervous structures. The prognosis for this type of injury is also the poorest, and
even with surgical repair and grafting, the results are not always rewarding. This type
of injury can be consequence of severe ischemia or nerve transection.63

The role of Schwann cells in peripheral nerve injuries

In the PNS, the Schwann cells are glial cells that produce myelin, which is
indispensable for fast conduction of nerve impulses. These cells additionally support
axonal regeneration by the provision of several neurotrophic factors, hence,
contributing to the creation of a microenvironment that is able to nourish, attract and
stimulate other cells to aid in nerve protection and regeneration after an injury.35,66

As is the case for other types of cells, there is not a sole marker for identifying Schwann
cells; a combination of known markers along with functional studies is preferred
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before inferring conclusions on the ability of MSCs to differentiate into Schwann-like
cells. Markers frequently used for the identification of Schwann cells are S100, p75,
Krox20, CD104, and glial fibrillary acidic protein (GFAP).46,49,50,56

S100 is the most commonly reported marker for Schwann cell. It is a calcium binding
protein constituted by 2 subunits: α and β (each approximately 10 kilo Daltons). It is
considered to be a cell growth regulator but has other functions such as a protein and
free fatty acid transport, or causing an increase in membrane permeability to cations,
which are likewise attributed to this protein. Cells known to express S100 are glial
cells, Schwann cells, melanocytes, chondrocytes, adipocytes, Langerhan’s cells,
interdigitating cells and some tumor cells (i.e. melanomas, Schwannomas).
Consequently, S100 is not a specific marker for Schwann cells; nevertheless, there have
been reports of undifferentiated MSCs expressing S100,46 implying the potential of
MSCs towards neural differentiation. In humans, cells expressing S100 have been
subclassified into cells that express S100b, S100a and S100ao. Schwann cells and cells
from the hypophysis express S100b.31 Other properties attributed to S100 are nerve
protection, nutrition and induction for axonal regeneration.46

GFAP is another marker commonly used to identify glial cells, including Schwann
cells. We have found, however, that undifferentiated equine MSCs also express this
protein, as previously reported by other researchers using undifferentiated MSCs
from other species.67,68 GFAP has neuroprotective properties by modulating the
Schwann cell response to nerve injury.46

Similarly important, as it was mentioned in previous sections with undifferentiated
MSCs, transplantation of either Schwann cells or MSCs differentiated into Schwannlike cells has been demonstrated to directly or indirectly enhance tissue healing by the
immunomodulatory, anti-inflammatory and paracrine functions that they exert on
target cells after an insult has occurred.
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Cell therapy for nervous tissue repair: current research

Studies performed in rats, guinea pigs, and rabbits have demonstrated that peripheral
nerves can be regenerated.26,48,54,69,70 Even though the outcome is often disappointing.
The most appropriate treatment for people with nerve injury is the insertion of an
autograft into the gap in the transected nerve.70-72 Limitations, such as available donor
nerves, donor-site morbidity, and limited supply of cultured Schwann cells, however,
prevent autografting from having practical clinical applications.26,72 This is one reason
why cell therapy with MSCs is intriguing; other factors include the ease of obtaining
and expanding these cells in vitro to yield a high number for transplantation.

Therapy with MSCs

During the past decade, research for treating peripheral nerve injuries has been
directed towards the use of cell therapy alone or combined with platelet rich plasma
(PRP), grafts, or tissue-engineered biomaterials. Experimental models in laboratory
animals and clinical trials in dogs have revealed that transplantation of either
undifferentiated MSCs or Schwann-like differentiated MSCs into animals with
peripheral nerve or spinal cord diseases results in positive outcomes.26,35,36,48,73,74 Better
results have been obtained with cells differentiated towards a Schwann-like cell
phenotype, based on histological and functional analyses.44,50,75 This emphasizes the
importance of cell therapy as a promising alternative to nerve grafting.

The processes by which undifferentiated MSCs or differentiated MSCs increase nerve
regeneration have not entirely been determined. It is known that MSCs possess certain
features that allow them to enhance tissue regeneration. When transplanted after
sciatic, femoral or facial nerve transection models in rats, MSCs appear to promote the
pattern for axonal regeneration and myelin production, as compared to controls
(usually, the contralateral limb or facial nerve). Quantitative morphometric evaluation
of the nerve involves axonal count and axonal diameter; the evaluation of myelin
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thickness provides extra information.76 These parameters seem improved on
laboratory animals that had been transplanted with MSCs after a nerve injury, when
compared to untreated controls. Functional analyses testing strength, length of stride,
and coordination are also superior results to the control limbs and to the animals that
were not treated with cell therapy.50,75

When the treatment consists of transplantation of purified Schwann cells from a fresh
peripheral nerve, or transplantation of Schwann cell-differentiated MSCs, the
aforementioned histological and functional results are superior to those obtained with
undifferentiated MSCs in laboratory animals.44,48,50,75

Delivery method. Cell therapy via transplantation of MSCs is one of the various
auxiliaries within the field of regenerative medicine. Other alternatives for aiding in
tissue repair include the use of other types of cells, platelet rich plasma (PRP), grafts,
scaffolds, and nanoparticles. Tissue engineering, for example, uses a combination of
transplanted cells, engineered scaffolds and biochemical factors to replace an injured
tissue or organ. Consequently, there is increasing interest on the design of
biomaterials capable of supporting cells and of promoting the delivery of factors
(growth factors, neurospheres, etc.) that most appropriately improve nerve
regeneration.

In laboratory animals the use MSCs or Schwann cell-differentiated MSCs for treating
peripheral nerve injuries (with or without a scaffold or autograft) is commonly
performed in situ immediately after nerve injury. There are several reports,
conversely, on clinical trials and experimental designs on peripheral nerve and spinal
cord injuries in which the transplantation of cells occurred intrathecally, by
administering the cells into the cerebrospinal fluid (CSF); intra-arterially (IA), or
intravenously (IV), via systemic or local administration.74,77,78 When MSCs are
transplanted IV, they are caught in the capillary beds of several tissues, mainly the
lungs.79 It is important to note that these cells were undifferentiated MSCs. To the
knowledge of the author, there are no reports regarding the administration of
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Schwann cell-differentiated MSCs via IV, CSF or IA routes for treating either spinal
cord or peripheral nerve injuries.

There are no current reports regarding the most suitable method of delivery of MSCs
for peripheral nerve disease in horses. Likewise, there are not reports regarding the
use of Schwann cell-differentiated MSCs for nervous tissue repair in horses.

Tracking MSCs after transplantation. The mechanisms by which MSCs are able to
migrate, stay (“homing”) and repopulate a tissue are not completely understood. In
vitro and in vivo studies have revealed that stromal derived factor-1 (SDF-1) and its
interaction with receptors CXCR1, 4 and CCR2 and 5, play roles in stem cell motility
and development. Furthermore, the expression of various types of adhesion
molecules, such as integrins, ICAMs and VCAMs, are also involved in stem cell
mobilization homing and proliferation.80-82 The phenomena of migration and homing
were evident in the repair of heart, bone, cartilage, CNS and PNS.47,81

For the sake of research it is important to be able to trace these cells after
transplantation. Relying solely on functional analyses or by improvement of
symptoms in humans does not assess the ability of cell therapy to contribute to tissue
repair, especially if medications and physical therapy were part of the treatment.
Methods to trace cells include labeling them with retroviral vectors to express
fluorescent proteins, and the use of commercial dyes. These methods, however,
require sacrificing of the animal to dissect the tissues. Alternatively, cells have been
tracked in vivo by imaging them via magnetic resonance (MRI), computed
tomography (CT), positron emission tomography (PET), and multiple photon
microscopy.83,84

Finally, the feasibility of these methods must be taken in consideration because of
issues regarding affordability and availability of equipment and reagents, false
positive signals, interference with the biological properties of MSCs, and most
importantly, the ability to accomplish any of these scans in a horse.
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Neurotrophic factors and nerve regeneration

A particular interest has been given to the paracrine features of MSCs to secrete
various trophic factors that aid in tissue repair. This is a topic of current focus because
of the ability of MSCs (in this case, differentiated towards a Schwann cell phenotype)
to be able to secrete neurotrophic factors that promote axonal regrowth and remyelination. These factors are thought to provide an appropriate microenvironment
for neuronal nourishment, survival and proliferation.34,66,72

Efforts have been made to understand the mechanisms of secretion, release and the
properties that neurotrophic factors exert over neural cells, regardless of their subtype. The ultimate purpose is to remove damaged cells and to restore myelin and
axonal regrowth after nerve injury by recruiting Schwann cells and other cells via cell
signaling. The exact mechanisms for secretion and release are not completely
understood yet. In vitro studies strengthen this hypothesis, after revealing that MSCs
from human adipose tissue or bone marrow are capable of expressing neurotrophic
factors and that they promote neurite process outgrowth when these cells are cocultured with injured nervous tissue.30,33,34,53

Some of the growth factors that have recently been investigated because of their effects
on nervous tissue repair are: NGF, brain-derived neurotrophic factor (BDNF), glial
cell line-derived neurotrophic factor (GDNF), ciliar neurotrophic factor (CNTF), ILGF1, and VEGF. Briefly, NGF acts on neurons to stimulate their proliferation and
differentiation; its action is potentiated when combined with scaffolds made of
biomaterials.85 Similarly, BDNF enhances MSC differentiation towards cells of
neuronal lineage in vitro, after nerve injury.85,86 In nerve fibers that were
experimentally transected, it was found that GDNF promotes myelination and axonal
re-growth on the early stages of the injury.87 Finally, CNTF, ILGF-1 and VEGF are
auxiliaries of nerve regeneration and survival, the last one mainly due to its location
between nerve fibers and blood vessels during nerve regeneration.31,88
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Overall, the ability of MSCs to inhibit the immune response created after allogeneic
transplantation, as well as their ability to contribute to tissue repair by direct or
indirect mechanisms makes MSCs an attractive therapeutic alternative in the field of
regenerative medicine.
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Abstract
Studies have shown that mesenchymal stromal cells (MSCs) are able to differentiate
into extra-mesodermal lineages, including neurons. Positive outcomes were obtained
after transplantation of neurally-induced MSCs in rats, rabbits and guinea pigs after
nerve injury, but this is unknown in horses. Our objective was to test the ability of
equine MSCs to differentiate into cells of neural lineage in vitro, and to assess
differences, if any, in morphology and lineage-specific protein expression.
Additionally, we wanted to investigate if horse age and cell passage number affected
the ability to achieve neural differentiation.

Bone marrow-derived MSCs were

obtained from 3 young and 4 adult horses. Following demonstration of stemness,
MSCs were neurally-induced and microscopically assessed at 3, 6, 12, 24 and 48 h.
Results showed that commercially available nitrogen-coated tissue culture plates
supported proliferation and differentiation. Morphological changes were observed as
early as 3 hours and all the cells surviving the treatment displayed a neural crest-like
cell phenotype. Expression of neural progenitor proteins, nestin, vimentin, β3 tubulin
and glial fibrillary acidic protein (GFAP), was assessed via western blot or
immunofluorescence. In our study, MSCs generated from young and middle-aged
horses did not show differences in their ability to undergo differentiation. The effect
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of cell passage number, however, is inconsistent and further experiments are needed.
Ongoing work is aimed to trans-differentiate these cells into Schwann cells for
transplantation into a peripheral nerve injury model in horses. The ultimate goal is to
provide practical resources for treatment of neuropathies in horses.

Keywords: Horse, mesenchymal stem cell, neuron, peripheral nerve, regeneration

Introduction

Spinal cord and peripheral nerve injuries in horses occur after trauma,
toxic/metabolic and infectious diseases. Less frequently, degenerative and hereditary
diseases also pose a threat. These events trigger an inflammatory cascade of events
that results in poor performance, disability or death. Additionally, the impact of
peripheral nerve injuries in horses is reflected by big financial and emotional
investments.

Peripheral nerves can be injured by thermal or chemical injuries,

compression, crushing, stretching or transection.1,2 After injury, the blood-nerve
barrier permeability increases and an inflammatory response is initiated resulting in
proliferation of Schwann cells and activation of local macrophages that respond to
tissue damage.2,3

Several of these cells secrete neurotrophic factors and other

substances that eventually enhance axonal regrowth and re-myelination, depending
on the magnitude of the lesion and the chronicity of it.1,2,4-10 A loss of axonal continuity
along with external nerve structures (neurotmesis, in the Seddon classification) has
the poorest prognosis for recovery.1

Mesenchymal stromal cells (MSCs) from bone marrow and adipose tissue have been
demonstrated to trans-differentiate into cells of other lineages other than mesodermal
lineages. In vitro research has shown the ability of rodent and human MSCs to acquire
a neural crest-like cell phenotype after induction with specific culture medium.7-9,11-13
Neural protein markers, mainly, vimentin, nestin, β3 tubulin and glial fibrillary acidic
protein (GFAP) were expressed in these neurally-induced cells, although results from
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different studies are contradictory and hence, inconclusive.10,13-18 Interestingly, a
novel study involving the evaluation of K+ and Na+ currents in neural crest-like cells
revealed that after chemical induction of rat MSCs, these cells appeared to have lost
the aforementioned electrophysiological property when compared to non-induced
MSCs; concluding that despite morphological and molecular changes similar to
neural cells, these chemically induced cells lacked the functional properties of
neurons.14 Nevertheless, several studies have shown positive correlation between in
vitro and in vivo results.2,7,9,12,14,19-21 For instance, bone marrow and adipose-derived
undifferentiated MSCs have revealed positive outcomes when these cells were
allogeneically transplanted in neurologically injured rats, rabbits and dogs.2,9-11,1820,22,23

On the other hand, studies in rats have also shown beneficial responses and

regain of nerve function after transplanting either chemically-induced MSCs into a
Schwann cell-like phenotype, or pure Schwann cells obtained from fresh peripheral
nerve tissue.9,11,23,24 It is important to mention, however, that in these studies cell
therapy occurred immediately after nerve or spinal cord injury.

To our knowledge, there are no reports in the literature that describe the ability of
equine bone marrow-derived MSCs (eBM-MSCs) to differentiate into cells of neural
lineage, or demonstrate the clinical benefits after transplantation into horses suffering
from neuropathies.

We have previously reported that to improve the clinical

outcomes related to stem cell therapies, it is important to assess the biology and
function of MSCs prior to their application in clinical cases.25 In view of our long term
goal of using equine MSCs in neuropathies, the present study was designed as a first
step to evaluate the proliferation and survival of eBM-MSCs in vitro, and their ability
to differentiate into neural crest-like cells after chemical induction. We compared
these properties and assessed changes, if any, in horses (donors) of two age groups.
Additionally, we compared changes in neural differentiation relative to the passage
number of eBM-MSC cultures.

We used the expression profiles of the neural

progenitor markers nestin, vimentin, β3 tubulin and GFAP to investigate these
changes.
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Materials and methods
1. Animals and bone marrow aspiration. Bone marrow aspirates were obtained from
the sternum of 2 young mixed breed (range: 1-4 years old) and 4 adult American
Quarter Horse (range: 9-13 years old) mares, and 1 young American Quarter Horse
gelding as described previously.26 All procedures were carried out as per an approved
protocol by the Institutional Animal Care and Use Committee of the University of
Tennessee, Knoxville, TN. Briefly, horses were sedated with 0.01-0.02 mg/kg of
detomidine hydrochloride, intravenously. A 10 cm band was clipped and surgically
prepared on the ventral aspect of the sternal area. Three mL of 2% lidocaine
hydrochloride were injected subcutaneously and intramuscularly at the level of the
5th or 6th sternebrae at the ventral midline, followed by a stab incision with a 15 blade
on the skin, subcutaneous tissue and musculature. A Jamshidi needle was inserted
perpendicular to the skin until it reached the periosteum. The needle was then forced
into the sternum and bone marrow from either the 5th or the 6th sternebrae was
obtained by gentle aspiration with a syringe loaded with 1000 IU/10 mL of heparin
sulfate.

2. Isolation and expansion of MSCs. These procedures were as described earlier.25-27
Briefly, bone marrow aspirate was diluted with 1X PBS and layered on top of the
lymphocyte separation media, Ficoll™. After centrifugation at 200g for 20 min at
room temperature, the buffy coat containing the mononuclear cells (MNCs) was
obtained. The MNCs were resuspended in growth media containing Dulbecco’s
modified Eagle medium/Ham’s F-12 [(DMEM-F12), Cellgro™, Manassas, Virginia],
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Roughly 20x106 cells
were seeded in 175 cm2 vented tissue culture flasks (Thermo Scientific™, Rochester,
NY), and maintained at 37 °C and 5% CO2. First growth medium change was carried
out between 5-7 days when clusters of colonies were visible under the phase contrast
microscope. When 70-80% confluency was reached, the cells were harvested with
0.25% trypsin-EDTA for 2 min at 37 °C (passage 1: P1). After centrifugation, the cell
pellet was reconstituted with either the growth medium to start a new experiment, or
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with freezing media containing 50% DMEM-F12, 50% FBS and 5% DMSO for
cryopreservation under liquid nitrogen for future experiments. These steps were
repeated as needed in order to obtain cells from passage 2 to 4 (P2 to P4; low passage),
and cells from P9-P12 (high passage) and used in future experiments.

3. Demonstration of stemness on low passage equine MSCs from 7 donors:
a) Colony forming unit assay (CFU). Passage 1 of equine MSCs were seeded at a

density of 1x106 in 100mm tissue culture dishes (Thermo Scientific™, Rochester, NY)
and maintained in growth medium for 7 to 10 days until clusters of colonies were
observed. The medium was replaced after every 2-3days. Colonies were fixed with
4% paraformaldehyde and stained with 0.5% of crystal violet (Sigma-Aldrich®, Saint
Louis, MO). After staining, the dishes were allowed to air dry and images were
acquired with a Fujifilm™ LAS-4000 imaging system (GE Healthcare Life Sciences).

b) MTS proliferation assay. Low passage (P2-P4) of equine MSCs were seeded at a

density of 2x104 per well in a 24-well tissue culture plate. The medium was replaced
every 2-3 days. Cell proliferation was measured at 2, 4 and 7 days post seeding. A
CellTiter 96 Aqueous non-radioactive (MTS) assay (Promega™, Madison, WI) was
used following the manufacturer instructions. Briefly, MTS reagent in a 5:1 ratio
relative to the media was added to each well and incubated for 3 h at 37 ° C and 5%
CO2. The absorbance at 490 nm was measured and data was obtained using Gen5
data analysis software (Biotek®, Winooski, Vermont). Growth medium only with no
cells was used as a blank to correct the readings for each of the samples.

c) Induction of adipogenic, osteogenic and chondrogenic differentiation. Low
passage (P2-P4) of equine MSCs were seeded at a cell density of 2x105cells in 60 mm
tissue culture dishes (BD Falcon™, New Jersey) and maintained at 37 ° C and 5% CO2
in growth medium. When the cells were roughly 70% confluent, the medium was
removed and was replaced with lineage-specific differentiation media as described
earlier.27 Briefly, adipogenic differentiation was induced by the addition of DMEMF12 medium containing 15% rabbit serum, 1 μmol/L dexamethasone, 10 μg/mL
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recombinant human insulin, 20 μmol/L indomethacin, and 0.5 mmol/L 3-isobutyl-1metylxanthine. Osteogenic differentiation was induced by the addition of DMEM-F12
medium containing 100 nmol/L /mL of dexamethasone, 0.25 mmol/L ascorbic acid
and 10 mmol/L β-glycerophosphate. Chondrogenic differentiation was induced by
the addition of DMEM-F12, 100 nmol/L of dexamethasone, 0.25 mmol/L ascorbic acid
and 5 ng/mL transforming growth factor β1. Medium was replenished every 2-3 days
and differentiation was monitored via microscopic evaluation.

Undifferentiated

MSCs maintained in regular growth medium without any differentiation reagents, for
the same number of days served as controls. Differentiation was confirmed using
lineage-specific cell staining using previously published methods.27

Specifically,

adipogenic cells were stained with Oil Red-O, osteogenic cells were stained with
Alizarin red, and chondrogenic cells were stained with Alcian blue. Images were
acquired with an electronic camera (Nikon™ DS-Fi2, Japan) connected to a Zeiss®
microscope and evaluated with the NIS-Elements™ imaging software (Nikon™).

4. Neural differentiation on low and high passage equine MSCs from selected donors.
These experiments were performed on equine MSCs obtained from one young and
one middle-aged donor. The donors were chosen based on their rates of proliferation
as demonstrated by the MTS assay described above.

a) Cell culture. Low (P2) and high (P9) of equine MSCswere seeded at a cell density
of 8 to 10x106 into either polystyrene, or Primaria™ nitrogen-coated 100 mm tissue
culture dishes (Becton Dickinson Labware, Bedford, MA). Cells were maintained in
regular growth medium at 37 ° C and 5% CO2, for at least 48 h to allow attachment.
Neural differentiation was induced using a combination of previously described
methods 13,18. Briefly, the growth medium was removed and cells were pre-incubated
with medium containing DMEM-F12, 20% FBS and 1 mM β-mercaptoethanol (SigmaAldrich®) at 37 °C and 5% CO2, for 18-24 h. Subsequently, the cells were induced by
the addition of the neural medium containing DMEM-F12, 2% DMSO and 200 µM
butylated hydroxyanisole (BHA; Sigma-Aldrich®) and cells were incubated at 37 °C
and 5% CO2, for 3, 6, 12, 24 or 48 h. Undifferentiated MSCs maintained in regular
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growth medium for the same number of hours were used as corresponding controls.
Undifferentiated and differentiated cells were assayed at the end of each experiment
as described below.

b) Nuclear/cytoplasmic staining. Nuclear/cytoplasmic fluorescent staining was used
to show the neural-cell like morphology of MSCs after neural differentiation. Low
and high passages of equine MSCs were seeded at a density of 1.25x106 on Primaria™
nitrogen-coated 60 mm tissue culture dishes and maintained in regular growth
medium at 37 °C and 5% CO2, for at least 48 h to allow attachment. When cells were
80-90% confluent they were chemically induced for neural differentiation as described
above. Undifferentiated control MSCs described above were maintained with regular
growth medium. For cytoplasmic staining, neurally-induced and undifferentiated
MSCs at 12 h were stained with 5 µg of WGA (wheat germ agglutinin, Alexa Fluor®
488 conjugate; Life Technologies™) for 10 min, at room temperature. To stain the
nucleus, cells were further washed and stained with 5 µg of TO-PRO®-3 iodide stain
(Life Technologies™, Grand Island, NY) for 10 min, at room temperature. After
washing, the cells were mounted with Slowfade® Gold antifade reagent (Molecular
Probes®, Grand Island, NY) and images were obtained with a laser scanning spectral
confocal microscope (Leica TCS SP2; Leica Microsystems©, Wetzlar, Germany), at 20x
and 63x magnification.

c) Protein extraction and western blot.

Total cell lysates were prepared from

undifferentiated and neuronally-induced equine MSCs from low and high passages
12 h post-differentiation using standard protocols. Cells on each dish were gently
washed with HBSS buffer and collected via cell scraping. To obtain total proteins in
each sample, cells were lysed in 200 µL of RIPA buffer (Boston Bioproducts™,
Ashland, MA), sonicated and supernatants were obtained by centrifugation. Total
protein in each sample was quantitated and concentrations were obtained using
modified BCA assay at 660nm (Pierce®, Thermo Scientific™). Equal concentrations
of total proteins from neurally-induced and undifferentiated MSCs were
electrophoretically separated in a 10% acrylamide gel and transferred onto
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nitrocellulose membranes. The membranes were blocked with 5% bovine serum
albumin (BSA) and incubated with mouse anti-β3 tubulin (1:1000; Santa Cruz™) and
mouse anti-GFAP (5 µg/10 mL; 1:1000; BD Pharmingen™). HRP goat anti-mouse IgG
(1:5000; BD Pharmingen™) was used as the secondary antibody. Antigen detection
was performed after exposure to ECL-2 reagent (Pierce®, Thermo Scientific™). Beta
actin was used as a loading control.

d) Immunofluorescence (IF). Low and high passages of equine MSCs were seeded at

a density of 1.25x106 on Primaria™ nitrogen-coated 60 mm tissue culture dishes and
maintained in growth medium at 37 °C and 5% CO2, for at least 48 h to allow
attachment. When cells were 80-90% confluent they were chemically induced for
neural differentiation as described above. Undifferentiated MSCs used as controls
were

maintained

with

regular

growth

medium.

Neurally-induced

and

undifferentiated MSCs were fixed with 4% paraformaldehyde, permeabilized with
0.1% Triton X-100 (Sigma®) for 10 min, at room temperature, and blocked with 5%
normal serum for 30 min, at room temperature. Cells were washed and incubated
overnight with 5 µg/sample of primary antibodies against nestin (BD Pharmingen™)
and vimentin (BD Pharmingen™), at 4 °C. After washing with HBSS buffer, cells were
incubated with the secondary antibody (Alexa Fluor® 647 donkey anti-mouse IgG at
5 µg per sample; BD Pharmingen™) for 20 min, at room temperature. The cells were
mounted with Slowfade® Gold antifade with DAPI reagent (Molecular Probes™) and
images were obtained with a laser scanning spectral confocal microscope (Leica TCS
SP2; Leica Microsystems©, Wetzlar, Germany)

Statistical analysis. A two-tailed Student’s t-test was used to compare the average of
neural – like cells, which adhered to the polystyrene-coated with those to the
Primaria™ nitrogen-coated tissue culture plates. Similarly, the expressions of nestin
and vimentin between cells of P2 and P9 from middle-aged horse, and between cells
of P2 from young and middle-aged horse were compared from the IF data. The
expressions of the two proteins were also compared between undifferentiated and
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neuronally-induced MSCs. Differences were considered statistically significant when
P<0.05.

Results
a) Stemness of equine MSCs
The stemness of cells from all equine MSC cultures was assessed solely in low passage
cells. Once the properties of stem cell were demonstrated, only 1 donor from each
group (young and middle-aged) was selected and the population of MSCs was
passaged for neural experiments.
Morphology. Equine MSC cultures expanded from the bone marrow harvest adhered
to the polystyrene surface and displayed spindle-shaped fibroblastic morphology. No
morphological change was observed in eBM-MSC cultures generated from young and
middle-aged donors.

Proliferation. Equine MSCs from young (Figure 2.1: horses 1-4) and middle-aged
donors (Figure 2.1: horses 5-7) were capable of self-renewal as demonstrated by their
proliferation and viability measured at days 2, 4, and 7. As demonstrated in the figure,
there was a 3-6 fold increase, in absorbance for all the donors over a period of 7 days
confirming their proliferation and viability. As expected and previously reported
cellular proliferation, was variable between each horse. Horses that showed the
highest proliferation and thus generating enough numbers of MSCs in a given period
of time were selected for all neural experiments (Donors 2 and 6).
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Figure 2.1. MTS proliferation assay on eBM-MSCs

CFU. Equine MSCs of P1 of young and middle-aged horses were capable of growing
in clusters over the polystyrene - coated tissue culture dishes at day10, suggesting that
the eBM-MSC cultures established represent the MSCs or the progenitor cells. A
representative CFU assay is shown (Figure 2.2).

Figure 2.2. Colony forming unit (CFU) assay of eBM-MSCs
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Mesodermal tri-lineage differentiation. Low passage equine MSCs from both young
and middle-aged donors were capable of differentiation into adipogenic,
chondrogenic and osteogenic cells under lineage-specific chemical induction (Figure
2.3). At day 5, adipogenic cells displayed a typical pattern of lipid droplet formation,
which could be stained with oil-red-o. Osteogenic and chondrogenic differentiation
potential was confirmed by Alizarin red and Alcian blue staining, respectively after
10-15 days of chemical induction. No morphological differences were observed
between horses. Variability existed, however, on the time of reaching a differentiated
phenotype, as judged by specific staining. Undifferentiated controls remained with a
spindle fibroblastic shape at all times and were not positive for lineage-specific
staining. Of importance and in accordance to our previously published paper 25,
osteogenic and chondrogenic differentiation of MSCs from one middle-age donor
(horse 6), consistently occurred earlier than the rest.

All data presented above confirm that equine MSCs generated from each donor are
progenitor cells, and they satisfy the criteria to be classified as the adult mesenchymal
stromal/progenitor cells.
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Figure 2.3. Mesodermal tri-lineage differentiation assays of eBM-MSCs

b) Neural differentiation
After ensuring selection of MSCs from low passage cells from the previous
experiments, eBM-MSCs were further expanded, passaged, and tested for neural
differentiation.

Neural crest-like cell morphology. For easy visualization, fluorescence microscopy
was used to show an intact nucleus and a “healthy” cytoplasm. TO-PRO®-3 stain, the
most sensitive probe for nucleic acid detection, along with WGA, specific to the cell
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membrane, were used to demonstrate the nucleus and the cytoplasmic structure of
the neural-like cells. Low and high passage eBM-MSCs from the selected young and
middle-aged horses were capable of adopting neural crest-like cell morphology as
early as 3 h after chemical induction. These morphological characteristics consisted
of elongation of the cell, cell body contraction, and formation of one or multiple cell
processes (Figure 2.4). After 12 h of neural differentiation, all the cells displayed
neural crest-like cell morphology. Moreover, these cells appeared to grow in a cluster
in a mesh-like pattern.

Undifferentiated controls had the spindle fibroblastic

appearance of a MSC.

No differences were microscopically observed on the

phenotypical characteristics of neural crest-like cells of low passage between young
and middle-aged horses. When analyzing high passage cells, subtle morphological
differences were detected.

The majority of these cells also displayed the

aforementioned neural crest-like cells characteristics; however, they seemed to lose
their cytoplasmic integrity and some of them appeared rounded and small. Nuclear
and cytoplasmic staining helped in visual assessment of the morphological
characteristics of these differentiated cells (Figure 2.5).

These morphological

differences were more specific to the passage numbers, i.e. can be attributed to the
process of cell culture itself, and not to the age of the donor.

Figure 2.4. Neural crest-like cell differentiation assay of eBM-MSCs
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Figure 2.5. Nuclear (TO-PRO-3-iodide)/cytoplasmic (WGA) staining of neural crestlike eBM-MSCs (a, b, c) and undifferentiated eBM-MSCs (d, f). Scale bar= 25 μm

Finally, as judged by the numbers of cells adhered to the 2 different types of tissue
culture plates; the nitrogen-coated plates (Primaria™) significantly enhanced cell
survival and proliferation roughly, 2-fold higher than the polystyrene – coated plates
(P=0.0319) after chemical induction (Figure 2.6).
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Figure 2.6. Nuclear (TO-PRO-3-iodide)/cytoplasmic (WGA) staining of neural crestlike eBM-MSCs on Primaria™ (a) and polystyrene-coated (b) tissue culture plates.
Scale bar= 100 μm

Expression of neural progenitor proteins. The expression of vimentin was confirmed
by IF (Figures 2.7 and 2.8). Vimentin was expressed by cells of low passage for both
age groups with no significant differences (P=0.7653); cell passage number did not
affect vimentin expression on the middle-age horse (P=0.7774), and no difference on
vimentin expression was noted between undifferentiated MSCs and neurally-induced
MSCs for young (P=0.9660) or middle-aged (P=0.1577) horses.
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Figure 2.7. Expression of vimentin in undifferentiated (top row) and differentiated
low passage eBM-MSCs (bottom row). Scale bar= 25 μm

Figure 2.8.

Expression of vimentin in undifferentiated (top) and differentiated

(bottom) high passage eBM-MSCs. Scale bar= 25 μm
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Immunoblot analysis was carried out to assess the expression of GFAP and β3 tubulin
(Figure 2.9). Differentiated cells from low passaged cells obtained from middle aged
and young MSC cultures showed the expression of both the GFAP and β3 tubulin. β3
tubulin, was not expressed in the differentiated cells from high passaged cells
obtained from the young MSC culture. The importance, if any, is not known at this
time. Interestingly, low and high passaged undifferentiated cells generated from both
donors expressed both proteins, suggesting plasticity of MSCs outside of mesodermal
lineages.

Figure 2.9. Western blot analysis of the expression of neural progenitor proteins β3
tubulin and GFAP in differentiated (a) and undifferentiated (b) eBM- MSCs generated
from low and high passaged cells from middle-aged (lanes 1 and 2, respectively) and
young (lanes 3 and 4, respectively) horses

We were not able to detect nestin expression by western blot analysis, even when 3
different primary antibodies with various dilutions (1:1000, 1:2000) or secondary
antibody concentrations (1:5000, 1:10 000).

Interestingly, nestin expression was

evident in undifferentiated and neurally-differentiated MSCs of low and high
passages for both age groups by IF (Figure 2.10). Nestin expression on cells of low
passage for both age groups was observed with no significant differences (P=0.7325).
Additionally, cell passage number did not affect significantly the expression of nestin
on the middle-aged horse (P=0.3467), and no difference on nestin expression was
noted between undifferentiated MSCs and neurally-induced MSCs for young
(P=0.9616) or middle-aged (P=0.0830) horses. A perinuclear location of nestin was
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evident on undifferentiated and neurally-differentiated MSCs of low passage, and on
undifferentiated MSCs of high passage both age groups (Figure 2.10). The location of
nestin in neurally-differentiated cells of high passage, however, was inconsistent, with
some cells displaying a perinuclear location and others showing a more diffuse,
cytoplasmic expression (Figure 2.11). It is possible that cells of high passages undergo
changes that alter the structure of some filamentous proteins (i.e. nestin).

Figure 2.10. Expression of nestin in differentiated (top) and undifferentiated (bottom)
low passage eBM-MSCs. Scale bar= 25 μm
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Figure 2.11. Expression of nestin in differentiated (top) and undifferentiated (bottom)
high passage eBM-MSCs. Scale bar= 25 μm

Discussion

Peripheral nerve injuries are a cause of poor performance in horses. These injuries are
difficult to manage and treatment mostly relies on physical therapy and antiinflammatories; however, the long-term effects are time and personnel consuming.
The development of neuronal cells is divided into various stages. After determination
of their fate, these cells migrate to specific locations of the nervous system and
accomplish different functions.18,28

Previous studies have demonstrated that

undifferentiated MSCs are able to express some neural protein markers, leading to the
question whether MSCs are in advance committed to a neural lineage.29-32 Moreover,
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as neural progenitors develop into more specialized cells, changes in protein markers
are also evident.4,13,17,30,33

Adipose-derived and bone marrow-derived MSCs from humans and rats are able to
differentiate into neural lineages.4,13,18,28,29,33-37

Several reports have described

different methods of chemical induction for neural differentiation.13,30,33,37,38 Medium
containing trans-retinoic acid or butylated hydroxyanisole is the most frequently
reported. Additionally, co-culture systems with MSCs and cells from nervous tissue
have also proven successful for the induction of neural differentiation of MSCs.29

We conducted chemical induction of bone marrow-derived MSCs from young and
middle-aged horses to characterize their viability and plasticity into mesodermal and
neuronal (ectodermal) lineages. Cells from all horses were capable of self-renewal
and underwent differentiation into adipogenic, osteogenic and chondrogenic
lineages. This was consistent with a previous report published from our laboratory25
and, thus, confirmed the stemness of the cultured MSCs.

For the neural

differentiation, fluorescence microscopy revealed that morphological changes were
observed as early as 3 h after chemical induction in all horses.

Using

nuclear/cytoplasmic staining we were able to demonstrate that differentiated cells
acquired a neural crest-like cell morphology in which retraction of the cell soma and
formation of multiple cell processes were observed.

Most importantly, the

proliferation of differentiated MSCs under the neural media was higher on the
nitrogen-coated plates (Primaria™) than on the polystyrene tissue culture plates,
suggesting stabilization of the cell membrane by providing a positive charge.

By the combination of western blot and IF analyses, we found that all MSCs,
undifferentiated and differentiated, expressed neural progenitor markers, namely,
vimentin, nestin, GFAP and β3 tubulin were evident. The expressions of GFAP and β3
tubulin in undifferentiated MSCs were particularly interesting and data is supported
by previous studies in rats and humans, suggesting their ability for neuronal
differentiation.39,40 Nestin has been shown to be expressed in muscle and neural

49

progenitor cells, as well as in highly proliferative cells (i.e. following injuries, high
mitotic rate, etc.) or undergoing development.41-43 In IF data, nestin subjectively
appeared weaker in cells from high passage than cells from low passage, suggesting
the loss of cellular mechanisms for proliferation and plasticity as the cell ages. We
detected a perinuclear location of nestin in undifferentiated and neurallydifferentiated MSCs from P2.

In differentiated cells from P9 in nestin location

extended from the perinuclear region towards other regions in the cytoplasm. This
was similar to previous reports43,44 and may suggest post-translational modifications
of nestin42-44, the analysis of which was beyond the scope of our study. Similarly, the
effect of cell passage number on the expression of these markers also suggested
modifications or structural changes as the cells age, but further studies are needed to
confirm this.

Our study mainly relies on morphological changes and neural marker protein
expression to describe the events occurring during neural differentiation of eBMMSCs. Our results agree with previous in vitro studies performed in bone marrowderived MSCs from rat, human and dogs in which eBM-MSCs are chemically induced
into cells that display morphologic, genetic and protein characteristics of neural
progenitors. To our knowledge, this is the first report describing the plasticity,
morphological characteristics and protein expression changes of eBM-MSCs into cells
of neural lineage after chemical induction. We have not only demonstrated the in
vitro differentiation patterns but also validated the cross-reactivity of human neuralspecific antibodies with equine protein samples.

Further studies are however,

warranted for investigating the functionality of these horse cells in vivo.
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CHAPTER III:
A PRELIMINARY, IN VIVO STUDY EVALUATING THE EFFECTS OF
MESENCHYMAL STROMAL CELLS IN SPEEDING REGENERATION OF
TRANSECTED PERIPHERAL NERVES OF HORSES
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Abstract
Peripheral nerve injuries cause poor performance in horses and their outcome is
frequently unfavorable. Autografting a peripheral nerve is the ideal approach for
repairing a nerve. This, however, represents difficulties in obtaining enough tissue
and in causing morbidity to the donor site. Alternative approaches include the
insertion of biocompatible scaffolds and transplantation of mesenchymal stromal cells
(MSCs) into the affected individual. Transplantation of MSCs differentiated into
Schwann-like cells is still under investigation, with promising results in laboratory
animals. There are no current reports of bone marrow-derived MSCs from horse and
their ability to differentiate into Schwann-like cells. Likewise, there are no reports
describing a model for peripheral nerve injury in horses. Our objectives were to
evaluate the ability of equine bone marrow-derived MSCs to differentiate into
Schwann-like cells, to propose a model for peripheral nerve injury in horses, and to
evaluate the effects of MSCs on nerve regeneration after transplantation in situ. Equine
bone marrow-derived MSCs were differentiated into Schwann-like cells for 7 days,
and assessed via microscopy, immunofluorescence and western blot by using
Schwann cell markers. Results showed that MSCs from young and middle-aged
horses displayed Schwann cell morphology and were able to express glial fibrillary
acidic protein and S-100b at day 7. Furthermore, histological analyses were performed
on peripheral nerve sections from 3 horses, 45 days after nerve transection followed
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by in situ transplantation of undifferentiated MSCs. Our fundamental goal is to
provide practical resources for treatment of peripheral nerve disease in horses.

Introduction
In veterinary medicine, horses can suffer peripheral nerve injuries after traumatism,
metabolic, toxic, hereditary, degenerative and infectious diseases. The sequels of
nerve injury in horses are frequently undesirable, resulting in poor performance,
disability or even death. This, consequently, causes a profound financial and
emotional impact afterwards.

Peripheral nerves have the ability to regenerate after injury due to the secretion of
cytokines and neurotrophic factors from the damaged cells (mainly by Schwann cells),
and because phagocytosis is initiated by local macrophages to remove cell debris.1-3
The regaining of nerve function, however, will depend on the magnitude of the nerve
lesion and its chronicity.4 The prognosis for recovery is poorest when a nerve is
transected and its nerve fibers and surrounding fascia (connective tissue) have been
completely disrupted. This is known as neurotmesis in Seddon’s classification for
peripheral nerve injuries.5,6 Surgical techniques for nerve repair involve suturing the
nerve stumps together or inserting a graft that bridges the gap. In tissue engineering,
some of the most commonly utilized materials for fabricating grafts or scaffolds
consist of vein, artery, nerve, silicone, collagen, laminin, gels made of platelet rich
plasma (PRP), and synthetic polymers.7,8 Regardless of the technique used or the
duration of the nerve repair, clinical results are often disappointing.6,9

Currently, research regarding cell therapy with mesenchymal stromal cells (MSCs)
suggests this might be an alternative approach for nervous tissue repair, including
spinal cord and peripheral nerve injuries.10-12 The neuroprotective effects of MSCs
have

been

widely

described,

and

they

involve

anti-inflammatory,

immunomodulatory, angiogenic and nurturing mechanisms.13-16 Furthermore, MSCs
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from bone marrow and adipose tissue are able to differentiate into Schwann-like cells
after chemical induction with specific conditions.12,17,18 In experimental models in
laboratory animals, when Schwann-like cells are transplanted into nervous lesions,
the results for axonal and myelin repair as well as the sensory and motor functions,
appear promising. This is believed to be consequence of the secretion of specific
neurotrophic factors that promote nerve repair.11,12,16

To our knowledge, there are no reports in the literature regarding outcomes of
peripheral nerve injuries after cell therapy in the horse. Similarly, we can find no
reports that describe the ability of equine bone marrow-derived MSCs (eBM-MSCs)
to differentiate into myelinated Schwann-like cells. We have recently reported that
eBM-MSCs are able to display morphological and protein characteristics of neural
progenitors. In this preliminary study, we evaluated the ability of eBM-MSCs to
differentiate into Schwann-like cells after chemical induction. Additionally, we
propose a new model for peripheral nerve injury in the horse and its outcome after
transplantation of undifferentiated MSCs.

Materials and methods
1. Animals.

Three healthy American Quarter Horse crossbred mares from our

Institution’s teaching herd were used for the study. The mares were transplanted
allogeneic undifferentiated MSCs from a donor whose cells have been previously
characterized. These cells were transplanted immediately after the first surgery (see
No. 2). All procedures were carried out as per an approved protocol by the
Institutional Animal Care and Use Committee of the University of Tennessee,
Knoxville, TN.

2. Transection of the ramus communicans with the horses standing. Horses were
sedated with 0.01-0.02 mg/kg of detomidine hydrochloride and 0.01-0.02 mg/kg of
butorphanol tartate, IV. The palmar aspect of both metacarpal regions was prepared
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for aseptic surgery and 2 mL of 2% mepivacaine hydrochloride were subcutaneously
deposited adjacent to the medial palmar nerve and adjacent to lateral palmar nerve
proximal to the palpable ramus communicans, palmar to the superficial digital flexor
tendon (Figure 3.1). A scalpel blade was used to create a cutaneous, longitudinal
incision over the ramus communicans. Using a 6 mm punch biopsy the center of this
anastomotic nerve, which connects the medial and lateral palmar nerves, was
removed and placed in formalin. Following nerve transection, 10x106 allogeneic
MSCs suspended in a volume of 1 mL of sterile saline were instilled into the fascia
surrounding this nerve (Figure 3.2). The contralateral transected nerve received an
injection with the same volume of sterile saline (control). The cutaneous incision was
closed with staples, and the distal portion of the limbs was bandaged. The horses
received phenylbutazone (4.4 mg/kg, PO) at the time of surgery and the day after
surgery (2.2 mg/kg, PO). The bandage was changed every third day until the staples
were removed at day 14. The horses underwent general anesthesia for complete
removal of both ramus communicans approximately 45 days after the cell transplant.
Briefly, the horses were induced with 0.5 mg/kg of xylazine and 2.2 mg/ kg of
ketamine, IV. They were intubated, placed in lateral recumbence, connected to the
ventilator and maintained with isofluorane. A scalpel blade was used to create a
cutaneous, longitudinal incision over the medial and lateral aspects of the ramus
communicans of both fore limbs. The subcutaneous tissue and surrounding fascia were
bluntly dissected and once the nerve was identified, it was exposed and transected
with scissors. The nerves were placed in Carson’s fixative and sent to pathology for
histological analyses. The horses received phenylbutazone (4.4 mg/kg, PO) prior to
surgery and the day after surgery. The bandages were changed every third day until
the staples were removed 14 days after surgery.
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Figure 3.1. Local anesthesia (nerve block) of the medial (a) and lateral (b) palmar
nerves of a horse

Figure 3.2. Dissection (a) and transection (b) of the ramus communicans of the fore limb
of a horse, followed by transplantation of undifferentiated MSCs (c)
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3. MSCs.

Low passage (P1 to P4) bone marrow-derived MSCs previously

cryopreserved from an allogeneic horse donor were used for cell expansion or for cell
transplantation into the mares. These MSCs had been previously characterized, as
described in the section of materials and methods of Chapter II (see “Demonstration
of stemness on low passage equine MSCs from 7 donors”).

4. Schwann cell differentiation.
a) Cell culture. Low passage (passage 1-5) equine MSCs were seeded at a cell density
of 8 to 10x106 into 100 mm Primaria™ nitrogen-coated tissue culture dishes (Becton
Dickinson Labware, Bedford, MA). Cells were maintained in regular growth medium
containing containing Dulbecco’s modified Eagle medium/Ham’s F-12 [(DMEMF12), Cellgro™, Manassas, Virginia], 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin, at 37 ° C and 5% CO2, for 48 h to allow attachment. Neural
differentiation was induced using a previously described method.12 Briefly, the
growth medium was removed and cells were pre-incubated with medium containing
DMEM-F12, 20% FBS and 1 mM β-mercaptoethanol (Sigma-Aldrich®) at 37 °C and
5% CO2, for 18-24 h. Subsequently, the cells were induced by the addition of the neural
medium containing DMEM-F12, 10% FBS and 35 ng/mL all-trans-retinoic acid for 3
days. The medium was then replaced with DMEM-F12, 10%FBS and a cytokine
cocktail containing: 5 μM forskolin, 200 ng/mL recombinant human heregulin-β1
(HRG-β1), 5 ng/mL platelet-derived growth factor, and 10 ng/mL recombinant
human basic fibroblast growth factor (all reagents from Sigma-Aldrich®), for 7 days,
replacing the medium every 72 h.

b) Nuclear/cytoplasmic staining. Equine MSCs were seeded at a density of 8-10x106
on 100 mm Primaria™ nitrogen-coated tissue culture dishes and maintained in
regular growth medium at 37 °C and 5% CO2, for 48 h to allow attachment. After 48h
when cells were 80-90% confluent they were chemically induced for Schwann cell
differentiation as described above. Undifferentiated MSCs (control) mentioned above
were maintained with regular growth medium. For cytoplasmic staining, Schwannlike cells and undifferentiated MSCs at 12 h were stained with 5 µg of WGA (wheat
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germ agglutinin, Alexa Fluor® 488 conjugate; Life Technologies™) for 10 min, at room
temperature. To stain the nucleus, cells were further washed and stained with 5 µg of
TO-PRO®-3 iodide stain (Life Technologies™, Grand Island, NY) for 10 min, at room
temperature. After washing, the cells were mounted with Slowfade® Gold antifade
reagent (Molecular Probes®, Grand Island, NY) and images were obtained with a
laser scanning spectral confocal microscope (Leica TCS SP2; Leica Microsystems©,
Wetzlar, Germany), at 20x and 63x magnification.

c) Protein extraction and western blot.

Total cell lysates were prepared from

Schwann-like cells and undifferentiated MSCs at 12 h using standard protocols. Cells
on each dish were gently washed with HBSS buffer and collected via cell scraping. To
obtain total proteins in each sample, cells were lysed in 200 μL of RIPA buffer (Boston
Bioproducts™, Ashland, MA), sonicated and supernatants containing total proteins
were obtained by centrifugation. Total proteins in each sample were quantitated and
concentrations were obtained using BCA assay at 660nm (Pierce®, Thermo
Scientific™). Equal concentrations (20 μg per lane) of total proteins from Schwann
cell-induced and undifferentiated MSCs were electrophoretically separated in a 12%
acrylamide gel and transferred onto nitrocellulose membranes. The membranes were
blocked with 5% bovine serum albumin (BSA) and incubated with mouse anti-S-100b
(1:1000; BD Pharmingen™), mouse anti-β3 tubulin (1:1000; Santa Cruz™) and mouse
anti-GFAP (1:1000; BD Pharmingen™).

HRP goat anti-mouse IgG (1:5000; BD

Pharmingen™) was used as the secondary antibody.

Antigen detection was

performed after exposure to ECL-2 reagent (Pierce®, Thermo Scientific™). Beta actin
was used as a loading control.

d) Immunofluorescence (IF). Low passage (P1-P5) MSCs from young and middleaged horse were seeded at a density of 8 to 10x106 cells on 100 mm Primaria™
nitrogen-coated tissue culture dishes and maintained in growth medium at 37 °C and
5% CO2, for at least 48 h to allow attachment. When cells were 80-90% confluent they
were

chemically

induced

for

neural
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differentiation

as

described

above.

Undifferentiated MSCs used as controls were maintained with regular growth
medium. Schwann cell-induced and undifferentiated MSCs were fixed with 4%
paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma®) for 10 min, at
room temperature, and blocked with 5% normal serum for 30 min, at room
temperature. Cells were washed and incubated overnight with 5 µg/dish of primary
antibodies against S-100b (BD Pharmingen™) and GFAP (BD Pharmingen™), at 4 °C.
After washing with HBSS buffer, cells were incubated with the secondary antibody
(Alexa Fluor® 647 donkey anti-mouse IgG at 5 µg per dish; BD Pharmingen™) for 20
min, at room temperature. The cells were mounted with Slowfade® Gold antifade
with DAPI reagent (Molecular Probes™) and images were obtained with a laser
scanning spectral confocal microscope (Leica TCS SP2; Leica Microsystems©, Wetzlar,
Germany).

5. Histological analysis of nerve tissue. The central portion the ramus communicans
transected from both fore limbs of each horse (n=3) during the first surgery was placed
on Carson’s fixative for histological analyses. Approximately 45 days after cell
transplantation, the whole nerve was collected from both fore limbs on these horses
placed on Carson’s fixative for histological analyses.

Results

1. Schwann cell differentiation

Schwann-like cell morphology. For better visualization, fluorescence microscopy
was used to show the integrity of nucleus and cytoplasm on the cells. TO-PRO®-3
stain, the most sensitive probe for nucleic acid detection, along with WGA, specific to
the cell membrane, were used to demonstrate the nucleus and the cytoplasmic
structure of the Schwann-like cells. Low passage MSCs from young and middle-aged
horses were capable of adopting a Schwann-like morphology 7 days after chemical
induction. The cells elongated until they displayed spindle-shape morphology and
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one or 2 cell processes appeared (Figures 3.3 and 3.4). At 4 days of chemical induction,
some of these cells began displaying this morphology, but at 7 days, most of the cells
were as described. Moreover, these cells seemed to grow in a “whorl-like” pattern.
Undifferentiated controls had the typical fibroblastic appearance of a MSC.

No

differences were microscopically observed in the phenotypic characteristics of
Schwann-like

cells

between

young

and

middle-aged

horses.

Subjectively,

approximately 80% of the cells had acquired a Schwann cell phenotype at 7 days after
chemical induction.

Figure 3.3. Phase-contrast microscopy of Schwann-like cells (black arrows) from
young (a) and middle-aged (b) horses
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Figure 3.4. Nuclear (TO-PRO-3-iodide)/cytoplasmic (WGA) staining of equine
Schwann-like cells. . Scale bar= 100 μm

Expression of Schwann cell markers. The expression of S-100b and GFAP was
confirmed by IF in Schwann-like cells from young and middle-aged horses (Figure
3.5). Immunoblot analysis via western blot also demonstrated the expression of S100b, GFAP and β3 tubulin on these Schwann-like cells. As reported in our previous
work (see Chapter II), undifferentiated cells generated from young and middle-aged
horses also expressed GFAP, suggesting that the ability of MSCs to differentiate into
other cell lineages goes beyond of mesodermal lineages. The expression of S-100b was
not evident in undifferentiated MSCs (Figure 3.6).
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Figure 3.5. Expression of Schwann cell markers S-100b (red) and GFAP (green) in
equine Schwann-like cells. Scale bar= 100 μm

Figure 3.6. Western blot analysis of the expression of β3 tubulin, GFAP and S-100b on
Schwann-like cells from middle-aged (lane 1) and young (lane 2) horses, and
undifferentiated MSCs from middle-aged (lane 3) and young (lane 4) horses

2. Peripheral nerve regeneration.
Five micrometer thick sections of Carson’s fixed, paraffin embedded tissues from the
sites of nerve transection and treatment, as well as adjacent segments of nerves, were
examined by light microscopy. The adjacent nerves in all specimens were considered
to be within normal limits (Figure 3.7). Both the saline and MSC treated sections in all
specimens had seroma formation characterized by cleft like spaces rimmed by or
partially filled by aggregates of fibrin overlain by/bordered by/ or partially infiltrated
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by fibroblastic cells and macrophages (Figure 3.8). Both the saline and cell treated
sections in all specimens had post traumatic, transactional neuroma formation
characterized by haphazard streams, whorls and fascicles of small vessels, fibroblasts
and Schwann cells (Figure 3.9). No localized or discrete population of undifferentiated
(i.e. MSC) or primitive cells (e.g. neural or Schwann cell progenitors) were recognized.

Figure 3.7. Nerves adjacent to the transection sites: saline injected (left) and MSC
injected (right). Hematoxylin and eosin stain. 100X magnification

Figure 3.8. Seromas at transection sites: saline injected (left) and MSC injected (right).
Hematoxylin and eosin stain. 100X magnification
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Figure 3.9. Neuromas at transection sites: saline injected (left) and MSC injected
(right). Hematoxylin and eosin stain. 100X magnification

Discussion

Peripheral nerves can be injured by chemical, thermal or mechanical trauma.19 Direct
traumatism, metabolic disease, or idiopathic disease such as damage to the branch of
the left recurrent laryngeal nerve (laryngeal hemiplegia) appears to be the nerve
injuries most commonly reported in the horse. Treatment with anti-inflammatories
and physical rehabilitation are often unrewarding. In human medicine when the
nerve fibers are transected, the ideal method for repair is closing the gap by suturing
the nerve endings and their surrounding fascia, or by inserting an autograft.7 The use
of autografts, however, is non-practical and can cause sequelae.20

The field of regenerative medicine is developing possible alternatives for nerve repair
by the use of cell transplantation alone or in combination with bioengineered
materials with the purpose of providing proper environmental conditions for survival
and proliferation of cells that will aid on nerve repair, particularly Schwann cells. 16,21
Based on experimental studies in laboratory animals, the transplantation of MSCs
after peripheral nerve injury results in regain of motor and sensory nerve
functions.11,16,22,23 Additionally, previous studies have demonstrated that MSCs are
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capable of extra-mesodermal differentiation, including cells from neural lineage.
Transplantation of MSCs differentiated into Schwann-like cells has revealed better
results on nerve function and morphology after nerve injury.10,11,24

We conducted chemical induction of low passage bone marrow-derived MSCs from
young and middle-aged horses to describe their plasticity into Schwann-like cells.
Phase-contrast and fluorescence microscopies revealed that morphological changes
were evident seven days after chemical induction in all horses. Differentiated cells
were elongated, with an oval-shaped cytoplasm, and the formation of one or multiple
cell processes. These cells appeared to grow in patches as compared to the flat even
layer that undifferentiated MSCs produce.

Western blot and IF analyses revealed the expression of the Schwann cell markers S100b and GFAP in Schwann-like cells. Undifferentiated MSCs also expressed GFAP,
as previously reported by our group (see Chapter II, manuscript under review), but
not S-100b. This suggests that bone marrow-derived MSCs are able to differentiate
into extra-mesodermal lineages25, including those from horses.

Moreover, we created a core lesion at the center of the ramus communicans in both fore
limbs of three horses. After this procedure, cell transplantation with allogeneic MSCs
was immediately performed in one of the limbs on all horses. Approximately 45 days
after these procedures, the horses underwent a second surgical procedure to reharvest the whole nerve on both fore limbs.

The in vitro portion of this study mainly relies on morphological and Schwann cell
protein markers to describe the events occurring during differentiation of equine bone
marrow-derived MSCs into Schwann-like cells. Our results agree with experiments
performed in bone marrow-derived MSCs from rats and humans, in which cells are
able to undergo differentiation and express typical Schwann cell markers.3,17,24,26

68

The in vivo portion of this study proposes a model for acute peripheral nerve injury in
the horse, which has not previously been reported. Additionally, we evaluated the
effects on speed and pattern of nerve regeneration after transplantation with
allogeneic MSCs. Cell transplantation with MSCs differentiated into Schwann-like
cells was not possible due to poor viability of the cells (25%) after detachment from
the tissue culture flasks. A method for optimizing collection of equine Schwann-like
cells is necessary. Furthermore, no histological differences were observed between
nerves treated with MSCs and saline (controls) after transection in all horses.
Additionally, there was no evidence of undifferentiated MSCs in the nerves that were
treated with MSC.

There are several limitations when working with large animal models. In the present
model for acute peripheral nerve injury in the horse, results are inconclusive due to
the low number of horses used and due to other factors that could have been involved
in nerve regeneration without the formation of seromas, such as surgical technique,
anatomical region of the artificially injured nerve (the distal limb of the horse has less
vasculature than other areas in the body), method of cell delivery, labeling and
tracking of cells, etc. In retrospective, we consider that transecting the center of the
ramus communicans with the horse under general anesthesia may provide a better
exposure of this nerve and the opportunity to close the surrounding nerve sheath and
inject the cells directly into the nerve. Likewise, closing the subcutaneous tissue may
prevent the formation of seromas.

To the knowledge of the authors, this is the first report describing the morphological
features and protein expression changes of equine bone marrow-derived MSCs into
Schwann-like cells. We have also validated the cross-reactivity of rat Schwann cellspecific antibodies with protein samples from horse. Further studies are warranted for
exploring the viability, homing, and functionality of both MSCs and Schwann-like
cells after transplantation in horses with peripheral nerve injuries. Similarly, a
practical and affordable method for delivering these cells is essential.
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CONCLUSION

This research focuses on evaluating and optimizing the in vitro conditions necessary
for equine bone marrow-derived MSCs to differentiate into cells of neural lineage. It
also describes the use of neural markers on equine MSCs or on protein samples
derived from equine MSCs, which has not been previously reported in the literature.
Subsequent work focuses on further optimization of in vitro conditions necessary for
committing these neural cells into Schwann cells. Finally, an in vivo project evaluating
a model of peripheral nerve transection in horses is presented for the evaluation of
nerve regeneration after undifferentiated MSCs are transplanted into the lesion
immediately after nerve injury.

Further research is required to investigate several aspects of peripheral nerve repair
in horses, including the optimization of a method for obtaining viable equine
Schwann-like cells after cultured in vitro, labeling of cells to track their migration after
transplantation in horses, studying the effects of inserting a scaffold with MSCs after
peripheral nerve injury in horses, and developing a practical and affordable method
of delivery of MSCs in the horse. These studies should combine in vitro and in vivo
findings for application in real cases in veterinary practice. The ultimate goal is to
provide alternative methods for peripheral nerve regeneration by using cell therapy
with MSCs and engineered biomaterials; consequently, improving not only the
performance but also the quality of life of horses affected with peripheral nerve and,
ultimately, spinal cord disorders.
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